126 related articles for article (PubMed ID: 38205512)
1. Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden.
Rögnvaldsson S; Thorsteinsdóttir S; Syriopoulou E; Sverrisdottir I; Turesson I; Eythorsson E; Oskarsson JT; Long TE; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Aspelund T; Gislason GK; Olafsson A; Sigurdsson JK; Hultcrantz M; Durie BGM; Harding S; Bjorkholm M; Landgren O; Love TJ; Kristinsson SY
Haematologica; 2024 Jan; ():. PubMed ID: 38205512
[TBL] [Abstract][Full Text] [Related]
2. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
3. Association Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance : An Analysis From a Population-Based Screening Study.
Sverrisdottir I; Thorsteinsdottir S; Rognvaldsson S; Aspelund T; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Thorsteinsdóttir I; Sveinsdottir SV; Palmason R; Olafsson I; Sigurdsson F; Thordardóttir AR; Eythorsson E; Jonsson A; Palsson R; Indridason OS; Gislason GK; Olafsson A; Sigurdsson J; Steingrímsdóttir H; Einarsson Long T; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY; Love TJ
Ann Intern Med; 2024 Jun; 177(6):711-718. PubMed ID: 38768457
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.
Rognvaldsson S; Eythorsson E; Thorsteinsdottir S; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Thorsteinsdóttir I; Olafsson I; Runolfsdottir HL; Helgason D; Emilsdottir AR; Agustsson AS; Bjornsson AH; Kristjansdottir G; Thordardottir AR; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Steingrimsdottir H; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Palsson R; Love TJ; Kristinsson SY
Blood Cancer J; 2021 Dec; 11(12):191. PubMed ID: 34853309
[TBL] [Abstract][Full Text] [Related]
5. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
Blood Cancer J; 2021 May; 11(5):94. PubMed ID: 34001889
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
[TBL] [Abstract][Full Text] [Related]
7. Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study.
Rögnvaldsson S; Aspelund T; Thorsteinsdóttir S; Turesson I; Björkholm M; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Jul; 107(1):137-144. PubMed ID: 33840154
[TBL] [Abstract][Full Text] [Related]
8. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.
Baldursdóttir TR; Löve ÞJ; Gíslason GK; Björkholm M; Mellqvist UH; Lund SH; Blimark CH; Turesson I; Hultcrantz M; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Mar; 106(3):380-388. PubMed ID: 33295006
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
11. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.
Steiner N; Göbel G; Suchecki P; Prokop W; Neuwirt H; Gunsilius E
Oncotarget; 2018 Jan; 9(2):2344-2356. PubMed ID: 29416776
[TBL] [Abstract][Full Text] [Related]
13. The Association of Agent Orange (AO) Exposure with Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Progression: A Population-based Study of Vietnam War Era Veterans.
Liu LW; Wang M; Grandhi N; Schroeder MA; Thomas T; Vargo K; Gao F; Sanfilippo KM; Chang SH
Res Sq; 2023 Oct; ():. PubMed ID: 37886452
[TBL] [Abstract][Full Text] [Related]
14. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
Go RS; Gundrum JD; Neuner JM
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
[TBL] [Abstract][Full Text] [Related]
15. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
Chang SH; Luo S; Thomas TS; O'Brian KK; Colditz GA; Carlsson NP; Carson KR
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040690
[TBL] [Abstract][Full Text] [Related]
16. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
17. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
Iwanaga M; Tomonaga M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
[TBL] [Abstract][Full Text] [Related]
19. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Landgren O; Hofmann JN; McShane CM; Santo L; Hultcrantz M; Korde N; Mailankody S; Kazandjian D; Murata K; Thoren K; Ramanathan L; Dogan A; Rustad E; Lu SX; Akhlaghi T; Kristinsson SY; Björkholm M; Devlin S; Purdue MP; Pfeiffer RM; Turesson I
JAMA Oncol; 2019 Sep; 5(9):1293-1301. PubMed ID: 31318385
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria.
Lewis E; Lee H; Fine N; Miller R; Hahn C; Tay J; Chhibber S; Mahe E; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):211-217. PubMed ID: 36621346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]